Sage Journals: Discover world-class research

Abstract

VEGF-A is a major angiogenesis and permeability factor. Its cellular effects, which can be used as targets in anti-angiogenesis therapy, have mainly been studied in vitro using endothelial cell cultures. The purpose of the present study was to further characterize these effects in vivo in vascular endothelial cells and pericytes, in an experimental monkey model of VEGF-A-induced iris neovascularization. Two cynomolgus monkeys (Macaca fascicularis) received four injections of 0.5 μg VEGF-A in the vitreous of one eye and PBS in the other eye. After sacrifice at day 9, eyes were enucleated and iris samples were snap-frozen for immunohistochemistry (IHC) and stained with a panel of antibodies recognizing endothelial and pericyte determinants related to angiogenesis and permeability. After VEGF-A treatment, the pre-existing iris vasculature showed increased permeability, hypertrophy, and activation, as demonstrated by increased staining of CD31, PAL-E, tPA, uPA, uPAR, Glut-1, and α_vβ₃ and α_vβ₅ integrins, VEGF receptors VEGFR-1, −2 and −3, and Tie-2 in endothelial cells, and of NG2 proteoglycan, uPA, uPAR, integrins and VEGFR-1 in pericytes. Vascular sprouts at the anterior surface of the iris were positive for the same antigens except for tPA, Glut-1, and Tie-2, which were notably absent. Moreover, in these sprouts VEGFR-2 and VEGFR-3 expression was very high in endothelial cells, whereas many pericytes were present that were positive for PDGFR-β, VEGFR-1, and NG2 proteoglycan and negative for α-SMA. In conclusion, proteins that play a role in angiogenesis are upregulated in both pre-existing and newly formed iris vasculature after treatment with VEGF-A. VEGF-A induces hypertrophy and loss of barrier function in pre-existing vessels, and induces angiogenic sprouting, characterized by marked expression of VEGFR-3 and lack of expression of tPA and Tie-2 in endothelial cells, and lack of α-SMA in pericytes. Our in vivo study indicates a role for α-SMA-negative pericytes in early stages of angiogenesis. Therefore, our findings shed new light on the temporal and spatial role of several proteins in the angiogenic cascade in vivo.

Keywords

angiogenesis vascular endothelial growth factor endothelial cells pericytes vascular permeability plasminogen activators integrins endothelial growth factor receptors angiopoietin

Tissue damage and ischemia stimulate endothelial cells and pericytes to acquire an angiogenic phenotype. These cells change from a quiescent state to an activated state. This requires expression of several specific proteins not expressed under normal conditions (Diaz-Flores et al. 1994; Ortega et al. 1997,1999; Risau 1997). In many ocular diseases, in which angiogenesis and increased permeability play a role, vascular endothelial growth factor (VEGF-A) has been identified as a major stimulating growth factor (reviewed in Ferrara 1999). VEGF-A is an angiogenesis factor acting through direct stimulation of its receptors (VEGFRs) on vascular cells, leading to increased permeability and neovascularization in vivo. Further-more, VEGF-A stimulates the key cellular processes of angiogenesis, such as activation of endothelial cells, breakdown of the extracellular matrix, and migration and proliferation of endothelial cells (Table 1). In endothelial cell cultures, VEGF-A induces expression of various molecules involved in the various steps of the angiogenesis process, such as urokinase-type and tissue-type plasminogen activators (uPA and tPA), uPA-receptor (uPAR), and α_vβ₃ and α_vβ₅ integrins (Pepper et al. 1991; Friedlander et al. 1995; Mignatti and Rifkin 1996; Suzuma et al. 1998). These molecules are important because they represent potential targets for anti-angiogenesis therapy in cancer and ocular diseases. However, the in vitro effects of VEGF-A have only sparsely been confirmed in in vivo studies (Nakata et al. 1998; Baker et al. 2000; Takano et al. 2000). It is often assumed that VEGF-A has the same effects on endothelial cells in vivo as it has in vitro. However, the local tissue environment, including other cell types, may distinctly influence the endothelial response to VEGF-A in vivo. One such cell type, the pericyte, plays an important role in addition to endothelial cells in the normal functioning of blood vessels (Hirschi and D'Amore 1996; Balabanov and Dore-Duffy 1998), but the involvement of pericytes in angiogenesis or the direct effects of VEGF-A on pericytes have rarely been studied (Grosskreutz et al. 1999). In fact, pericytes are generally believed not to be involved in the early angiogenic response but rather in the later maturation phases of vascular growth (Benjamin et al. 1998). VEGF-A may also act on pericytes (Takagi et al. 1996) in concert with other growth factors, such as platelet-derived growth factor-BB (PDGF), which is secreted by endothelial cells. Its receptor (PDGFR-β) is found on pericytes. PDGF is essential for proliferation and migration of pericytes along capillaries (Lindahl et al. 1997). In addition, (pericyte-derived?) angiopoietin-1 acting on endothelial Tie2 induces vascular maturation and integrity (Sato et al. 1995).

Table 1

Key processes in angiogenesis, their marker antigens, and staining intensities of these markers of angiogenesis in endothelial cells (ECs) and pericytes (PCs) in monkey iris after VEGF-A treatment or in control eyes (PBS): VEGF-A-induced effects were scored in pre-existing and newly formed vessels a

Process	Antigen	Marker	Reference b	PBS	VEGF Pre-existing vessels	VEGF Newly formed vessels
Permeability	PAL-E	Non-barrier vascular endothelium	1, 2	–	+ +	+ +
	IgG	Extravasated plasma proteins		–	+ +	+ +
	Fibrinogen	Extravasated plasma proteins		+	+ +	+ +
	Glut-1	Barrier endothelium	3	+	+ +	–
Cellular activation
ECs	CD31	All endothelium		+	+ +	+ +
	VEGFR-2	VEGF-A receptor 2 (KDR/Flk-1)		±	+	+ +
	VEGFR-3	VEGF-C/-D receptor 3 (Flt-4)		–	+	+ +
PCs	NG2	Activated pericytes	4, 6	±	+	+ +
	PDGFR-β	PDGF receptor-β		±	+
ECs and/or PCs	VEGFR-1	VEGF-A receptor 1 (Flt-1)		±	+ +	+ +
Breakdown of extracellular matrix
ECs	tPA	Tissue plasminogen activator	5	±	+	-
	uPAR	Urokinase PA receptor		±	+ +	+ +
ECs and/or PCs	uPA			±	+	+
Migration
ECs and/or PCs	α_vβ₃	Integrin	6	–/±	+ +	+ +
	α_vβ₅	Integrin		±	+ +	+ +
Maturation
ECs	Tie-2	Angiopoietin receptor		+	+ +	–
PCs	α-SMA	Pericytes	7	+	+	–

^a–, no staining; ±, weak staining; +, moderate staining; ++, strong staining.

^b1, Schlingemann et al. 1985; 2, Schlingemann et al. 1997; 3, Albrecht et al. 1990; 4, Schlingemann et al. 1990b; 5, Mignatti et al. 1996; 6, Eliceiri et al. 2000; 7, Schlingemann et al. 1991.

In a monkey model, elevated VEGF-A levels are temporally and spatially correlated with retinal ischemia-induced iris neovascularization (Miller et al. 1994), and VEGF-A has been shown to be necessary for iris neovascularization in this model (Adamis et al. 1996). Injections of VEGF-A into the vitreous of the eye in a primate also induce iris neovascularization (Tolentino et al. 1996). This established model allows easy distinction between pre-existing vasculature in the iris stroma and newly formed vascular sprouts at the anterior surface of the iris. The purpose of the present study was to characterize effects of VEGF-A on a series of molecules involved in key events in angiogenesis in the vasculature of the iris and to define the phenotype of the induced neovasculature.

Materials and Methods

Monkey Tissue Samples

Two cynomolgus monkeys (Macaca fascicularis), a 15-year-old male and a 5-year-old female, were used. Both animals had been used in behavioral studies in the past, not involving known effects on the eyes. Animal care and experimental treatment were carried out following the Association of Research in Vision and Ophthalmology guidelines for animal experimentation and in accordance with the guidelines for animal care at the University of Nijmegen, The Netherlands.

The experimental design has been described previously (Hofman et al. 2000). Briefly, the animals received four injections at days 0, 2, 4, and 7 with PBS in the left eye (50 μl) through the pars plana into the center of the vitreous using a 30-gauge needle, and four injections with bioactive human recombinant VEGF-A (Harbor Bio-products, Norwood, MA; 0.5 μg in 50 μl sterile PBS), in the right eye on the same days. Before intravitreal injection, 20 mg/kg ketamine HCl (Ketalar), 0.005 mg/kg acepromazine, and 0.03 mg/kg atropine sulfate were given intramuscularly for general anesthesia. Each day the anterior segment was studied using biomicroscopy and photographed using a handheld camera (Kodak; Rochester, NY). Ten minutes after injection, intraocular pressure was measured using a Schiotz tonometer (Sklar Manufacturing; New York, NY). The two animals were sacrificed on day 9 with a bolus of 7 mg/kg IV pentobarbital (Nembutal). After enucleation, eyes were dissected and parts of the iris and anterior segment were snap-frozen in liquid nitrogen and stored at −70C until used.

Immunohistochemistry

Air-dried cryostat sections (8 μm thick) were fixed in cold acetone for 10 min and stained by an indirect immunoperoxidase procedure. Endogenous peroxidase activity was quenched by incubating sections for 20 min in a solution of 0.1% sodium azide and 0.03% H₂O₂ in PBS. To reduce nonspecific staining and to block endogenous biotin, sections were preincubated with a solution containing 10% normal goat serum (Jackson ImmunoResearch Laboratories; West Grove, PA), 5% avidin (DAKO; Glostrup, Denmark), and 0.05% saponin (Sigma; St Louis, MO) in PBS for 15 min. Sections were subsequently incubated overnight at 4C with the following monoclonal antibodies: PAL-E (dilution 1:1000; Schlingemann et al. 1985,1997), anti-CD31 (EN-4; Sanbio, Uden, The Netherlands; dilution 1:500); anti-NG2 proteoglycan (formerly known as high molecular weight-melanoma associated antigen (HMW-MAA), a chondroitin sulfate proteoglycan; clone 225.28S, a kind gift from Prof. S. Ferrone, Roswell Park Cancer Institute, Buffalo, NY; dilution 1:500; Schlingemann et al. 1990b), anti-α_vβ₃ integrin (clone 23C6; a kind gift from Prof. M.A. Horton, Bone and Mineral Center, University Center, London, UK; dilution 1:500), anti-α_vβ₅ integrin (P1F6; Gibco BRL, Rockville, MD; dilution 1:500), anti-PDGFR-β (a kind gift from Dr. K. Rubin, Uppsala, Sweden; dilution 1:500), anti-VEGFR-1 and anti-VEGFR-2 (kind gifts from Dr. H.A. Weich, Braunschweig, Germany; dilution 1:400), anti-VEGFR-3 (a kind gift from Prof. K. Alitalo, Haartman Institute, Helsinki, Finland; dilution 1:1500), anti-uPAR (Boehringer-Mannheim, Weidel, Germany; dilution 1:250), anti-tPA (a kind gift from Prof. V.W.M. van Hinsbergh, Gaubius Laboratory TNO-PG, Leiden, The Netherlands; dilution 1:200), anti-fibrinogen (Y-18, a kind gift from Dr. J.J. Emeis, Gaubius Laboratory TNO-PG, Leiden, The Netherlands; dilution 1:100), anti-Glut-1 (a kind gift from Dr. L. Andersson, Pharmacia & Upjohn, Uppsala, Sweden; dilution 1:250; Harik et al. 1993), and anti-α-SMA (DAKO; dilution 1:250; Schlingemann et al. 1991), and the polyclonal antibodies: rabbit anti-uPA (a kind gift from Prof. V.W.M. van Hinsbergh; dilution 1:1000) and anti-IgG conjugated with horseradish peroxidase (HRP; DAKO; dilution 1:100).

Sections were rinsed, incubated with goat anti-mouse immunoglobulins conjugated with biotin (Histostain Plus kit; Zymed, San Francisco, CA) for 15 min except for the sections incubated with anti-uPA, which were incubated with goat-anti-rabbit IgG conjugated with HRP (GAR-PO; DAKO), and the sections incubated with anti-IgG-HRP. All sections except for those incubated with anti-uPA and anti-IgG were incubated with a streptavidin-HRP complex. Peroxidase activity was visualized using 3-amino-9-ethylcarbazole (AEC; Sigma) and 0.01% H₂O₂. The reaction was terminated by rinsing the sections with distilled water. Counterstaining was performed with hematoxylin. Sections were washed and coverslipped in glycerol/glycerin (Sigma). Control sections were incubated in the absence of primary antibodies.

Results

Biomicroscopy

In the two VEGF-A-injected monkey eyes, transient fibrin deposition in the anterior chamber (AC) was detected at day 4. Overt neovascularization of the iris was observed at days 8 and 9 (Figure 1A). In the PBS-injected eyes, these effects were not found (Figure 1B). Apart from fibrin deposition in the AC of VEGF-A-injected eyes on day 4, the eyes did not show signs of inflammation. Intraocular pressure always remained below 25 mmHg.

Immunohistochemistry

Results of the phenotypic IHC characterization of the iris vasculature are summarized in Table 1. The VEGF-A-injected eyes and PBS-injected eyes of the two monkeys showed identical staining patterns for all markers studied. A schematic representation of a cross-section of the anterior segment, with a detail of the iris, is shown in Figures 1C and 1D.

In VEGF-A-injected eyes, CD31 (EN4; Figures 2A and 2B) staining of endothelial cells confirmed the presence of the biomicroscopically observed iris neovascularization and demonstrated hypertrophy of pre-existing iris vasculature. Formation of many sprouting vascular structures in the superficial (anterior) stroma and at the surface of the iris was the most important evidence for neovascularization. In PBS-injected eyes, few or no microvessels were present at the surface of the iris. The pre-existing iris vasculature developed a more tortuous (Figure 2A) and hypertrophic morphology under the influence of VEGF-A compared with iris vessels of control eyes.

Figure 1

Biomicroscopy of VEGF-A-injected eye (A) and PBS-injected eye (B), and a schematic representation of a cross-section of the anterior segment of the eye (C), with a detail of the iris (D) as it appears in the subsequent Figures 2–6 of monkey sections. Figures C and D are from Clinical Symposia: Volume 14, Issue #4, Plate VIII. (Copyright 1962. Icon Learning Systems, LLC, a subsidiary of MediMedia USA Inc. Reprinted with permission from ICON Learning Systems, LLC, illustrated by Frank H. Netter, MD. All rights reserved.)

Markers of Vascular Permeability

In VEGF-A-injected eyes, marked staining of endogenous IgG (Figure 2E) and fibrinogen (Figure 2G) was found in iris stroma, indicating increased permeability of the iris microvasculature. These “leaky” vessels stained for endothelial antigen PAL-E (Figure 2C) whereas staining of this antigen and IgG was absent in the iris of control eyes (Figure 2D and 2F). In VEGF-A-injected eyes, capillaries in the iris base and some capillaries in the ciliary muscle adjacent to the iris base also showed increased staining of PAL-E, with a clear gradient of decreasing vascular staining from the iris base to the ciliary muscle (not shown). As uveoscleral outflow of aqueous humour occurs through this area, this staining gradient suggested an outflow-related concentration-response effect of the exogenous VEGF-A on local blood vessels. Staining for fibrinogen was confined to the blood vessels in the PBS-injected eye (Figure 2H).

Staining of the blood-brain barrier marker Glut-1 was observed in the iris microvasculature of control eyes (Figure 2J). In VEGF-A-injected eyes, Glut-1 staining was more intense in the pre-existing vasculature (Figure 2I). The newly formed vessels did not stain with anti-Glut-1 (Figure 2I).

Markers of Cellular Activation

In VEGF-A-injected eyes, staining of CD31 was more prominent in pre-existing iris vasculature and newly formed vessels at the iris surface compared to iris vessels in the PBS-injected eyes (Figures 2A and 2B).

Figure 2

Immunohistochemical staining of endothelial antigens CD31 (A,B), PAL-E (C,D), IgG (E,F), fibrinogen (G,H), and Glut-1 (I,J) in serial sections of the iris of a monkey eye. In all figures, arrows indicate examples of pre-existing blood vessels and arrowheads examples of newly formed blood vessel sprouts. Red color represents positive staining, brown color represents iris pigment. CD31 staining (A) confirms the presence of the biomicroscopically observed iris neovascularization (Figure 1), in which PAL-E (C) is also present. In addition, PAL-E is expressed in pre-existing vessels, indicating that in these vessels and in the newly formed vessels the barrier function is lost. IgG and fibrinogen are diffusely present in the iris stroma of the VEGF-A-injected eye (E,G), consistent with a loss of barrier function of the iris vasculature. Glut-1 is expressed in pre-existing vessels of both the PBS- and VEGF-A-injected eyes (I,J), whereas Glut-1 is not present in the newly formed vessels in the VEGF-A-injected eye (I). Asterisk, pupillary sphincter muscle; AC, anterior chamber; IP, iris pigment. Bar = 40 μm.

Activated pericytes were recognized by increased staining of the marker for this cell type, NG2 proteoglycan, in the iris of VEGF-A-treated eyes (Figure 3C). Staining of this antigen was also found in newly formed vessels at the iris surface, indicating that these sprouts consisted of both endothelial cells and pericytes (Figures 3C and 6I). Pericytes in control eyes were weakly stained for NG2 proteoglycan (Figure 3D). In both control eyes and VEGF-A-injected eyes, staining of VEGFR-1 was observed in pre -existing iris microvasculature, in a pattern that suggested expression in more than just endothelial cells compared to CD31, i.e., also in pericytes (Figures 4A, 4B, and 6A). VEGFR-1 staining was more distinct in VEGF-A-injected eyes, both in pre-existing vessels and vascular sprouts. VEGFR-2 staining was weak in iris vessels of control eyes. It was upregulated in pre-existing vessels but more strongly in newly formed vessels in VEGF-A-injected eyes (Figures 4C, 4D, and 6B). A different staining pattern was found for VEGFR-3 (Figures 4E, 4F and 6C). It was absent in control eyes whereas in VEGF-A-injected eyes strong expression was observed, particularly in newly formed vessels. Staining of VEGFR-2 and VEGFR-3 appeared to be confined to endothelial cells (Figures 6B and 6C). When VEGFR-2 and VEGFR-3 staining with VEGFR-1 staining were compared (exemplified in Figures 4A, 4C, 4E, and 6A-6C), more elements of a vascular wall were stained for VEGFR-1 than for the two other receptors.

Staining of PDGFR-β was found in pericytes of preexisting iris microvasculature in control eyes (Figure 4H), and was stronger in VEGF-A-injected eyes (Figure 4G). PDGFR-β staining was observed in pericytes in vascular sprouts at the iris surface in a pattern similar to that of NG2 proteoglycan (Figure 6F).

Proteins Involved in Fibrinolysis and Breakdown of Extracellular Matrix

tPA was present in a number of iris vessels of control eyes. It was localized in endothelial cells but also in a more diffuse distribution pattern in the vascular wall (Figure 5F). In hypertrophic iris vessels of VEGF-A-injected eyes, tPA staining was slightly stronger, but newly formed vessels and sprouts at the iris surface were distinctly negative (Figures 5E and 6J). In contrast, staining of uPA was marked in both pre-existing vessels and newly formed vessels, including the tips of sprouts at the iris surface, indicating expression of uPA by both quiescent and migrating cells (Figure 5A). The staining pattern suggested localization of uPA in endothelial cells and pericytes in positive vessels, and it was always co-localized with uPAR. Staining of uPAR was observed in all cell types in control and VEGF-A-injected eyes, but expression was stronger after VEGF-A treatment (Figures 5C and 5D).

Proteins Involved in Endothelial and Pericyte Migration

Control eyes showed absent to weak vascular staining of α_vβ₃ (Figure 5H) and α_vβ₅ integrins (Figure 5J). The staining pattern suggested expression of α_vβ₃ and α_vβ₅ in pericytes and/or at the abluminal side of endothelial cells (Figures 6K and 6L). In VEGF-A-injected eyes, staining of α_vβ₃ and α_vβ₅ was much stronger, but staining intensity was similar in pre-existing and newly formed vessels, indicating expression of both integrins by quiescent and migrating cells (Figures 5G and 5I).

Markers of Maturation and Differentiation

α-SMA, a marker for smooth muscle cells and resting pericytes (Schlingemann et al. 1991), was stained in a few iris vessels in PBS-injected eyes and pre-existing vessels in VEGF-A-treated eyes. However, activated pericytes in angiogenic sprouts at the iris surface in VEGF-A-injected eyes showed no or only weak and fragmented staining of α-SMA (Figures 3E, 3F, 6G, and 6H).

Tie-2 was present in iris microvasculature in control eyes. In eyes injected with VEGF-A, staining of pre-existing vessels was more intense, whereas Tie-2 staining was absent in newly formed vessels (Figures 3A, 3B, 6D, and 6E).

Discussion

The results of our IHC study in the monkey iris after VEGF-A treatment show prominent changes in expression patterns of molecules that are functional in angiogenesis. Our results allow characterization of an in vivo angiogenic phenotype of endothelial cells and pericytes in VEGF-A-induced neovascularization (Figure 7). This in vivo study confirms a number of in vitro studies (Pepper et al. 1991; Friedlander et al. 1995; Van Hinsbergh et al. 1997; Plate and Warnke 1997; Suzuma et al. 1998) that investigated effects of VEGF-A on cultured endothelial cells, but several of our observations may help to shed new light on functional aspects of angiogenesis in vivo.

The various stages of angiogenesis have been defined in morphological studies (Ausprunk and Folkman 1977; Paweletz and Knierim 1989; Schlingemann et al. 1990b,1991; Paku and Paweletz 1991; Nehls et al. 1992). In an early phase, i.e., within a few hours to a few days after exposure to an angiogenic stimulus, capillary permeability increases and the normally highly differentiated, flattened endothelial cells and adjacent pericytes become activated, displaying hypertrophy and an increased number of organelles. In line with these observations, at 9 days after repeated VEGF-A exposure, the pre-existing iris vasculature was hypertrophic in our model, as was shown by staining patterns of the pan-endothelial marker proteins CD31. Capillary permeability was increased, as was shown by the extensive leakage of plasma proteins IgG and fibrinogen into the iris stroma. This VEGF-A-induced increased permeability of the preexisting vasculature was accompanied by expression of PAL-E, a non-barrier vascular endothelium marker absent in normal iris vasculature (Schlingemann et al. 1997). Glut-1 is a membrane glucose transporter, which is characteristically expressed on blood-brain barrier endothelium (Harik et al. 1993). However, Glut-1 is upregulated in several pathological conditions in the eye associated with VEGF-A activity (Kumagai et al. 1994). In vitro, Glut-1 was found to be translocated from the cytoplasm to the plasma membrane under the influence of VEGF-A, which enhanced glucose transport into retinal endothelial cells (Sone et al. 2000). Our in vivo results of stronger Glut-1 staining of pre-existing vessels of the iris in VEGF-A-injected eyes compared with those in control eyes are consistent with these in vitro findings. The newly formed vessels at the anterior surface of the iris did not express this marker, which is in agreement with the observation that immature blood-brain barrier endothelium does not express Glut-1 (Albrecht et al. 1990).

Figure 3

Immunohistochemical staining of angiopoietin receptor Tie2 (A,B), activated pericyte marker NG2 proteoglycan (C,D), and α-SMA (E,F) in the VEGF-A-injected eye (A,C,E) and PBS-injected eye (B,D,F). Tie2 is present in the pre-existing iris vasculature of both the VEGF-A-injected eye (A) and the PBS-injected eye (B) but is absent in newly formed vessels (A). Note strong NG2 proteoglycan expression in newly formed vessels (C), whereas the commonly used pericyte marker α-SMA is only sporadically present (E). Asterisk, pupillary sphincter muscle. Bar = 30 μm.

Figure 4

Immunohistochemical staining of VEGFR-1 (A,B), VEGFR-2 (C,D), VEGFR-3 (E,F), and PDGFR-β (G,H) in the VEGF-A-injected eye (A,C,E,G) and PBS-injected eye (B,D,F,H). VEGFR-1 is present in the pre-existing iris vasculature of both the VEGF-A-injected eye (A) and the PBS-injected eye (B) and in newly formed vessels (A), in a pattern that suggests VEGFR-1 expression in pericytes. Note strong expression of VEGFR-2 (C) and VEGFR-3 (E) in newly formed vessels compared with pre-existing vasculature in the VEGF-A-injected eye. VEGFR-2 is weakly expressed in pre-existing vasculature of the PBS-injected eye (D), whereas VEGFR-3 is absent in these vessels (F). PDGFR-β is present in pericytes in pre-existing vessels of both VEGF-A- and PBS-injected eyes (G,H) and in newly formed vessels (G). Note that in all sections of the VEGF-A-injected eye, the iris is folded. Bar = 30 μm.

Figure 5

Immunohistochemical staining of uPA (A,B), uPAR (C,D), tPA (E,F), α_vβ₃ (G,H), and α_vβ₅ (I,J) in the VEGF-A-injected eye (A,C,E,G,I) and the PBS-injected eye (B,D,F,H,J). Note uPA staining in pre-existing and newly formed vessels and strong uPAR expression in all cell types in PBS- and VEGF-A-injected eyes. tPA is present in pre-existing vessels of both VEGF-A- (E) and PBS-injected eyes (F), whereas it is absent in newly formed vessels. Expression of α_vβ₃ and α_vβ₅ is found in all iris vessels in the VEGF-A-injected eye (G,I), whereas weak to no expression is found in the PBS-injected eye (H,J). The staining pattern of these integrins suggests expression in both endothelial cells and pericytes. Note that in all sections of the VEGF-A-injected eye, the iris is folded. Bar = 30 μm.

Figure 6

High-power magnifications of staining of VEGFR-1 (A), VEGFR-2 (B), VEGFR-3 (C), Tie2 (D,E), PDFGR-β (F), α-SMA (G,H), NG2 (I), tPA (J), α_vβ₃ (K), and α_vβ₅ (L) in angiogenic sprouts (A-D,F,G,I,J) and pre-existing vessels (E,H,K,L) in the VEGF-A-injected eye. Note the endothelial cell and/or pericyte-like staining pattern of VEGFR-1, α_vβ₃, and α_vβ₅, specific endothelial staining of VEGFR-2, VEGFR-3, and Tie2, and specific pericyte staining of PDFGR-β, α-SMA, and NG2. Moreover, note absent expression of Tie2 and α-SMA in newly formed (D,G) compared to pre-existing vessels (E,H).

Activation of endothelial cells and pericytes in preexisting iris vessels after VEGF-A treatment was indicated by increased staining of several antigens, including VEGFRs. In vivo, quiescent endothelial cells and pericytes are considered to lack expression of VEGFRs (Ortega et al. 1999), although we have found recently that VEGFRs are also expressed under physiological conditions (Witmer et al. 2002b). However, when VEGF-A is present in vivo, e.g., in tumors, VEGFRs are invariably expressed at a high level (Dvorak et al. 1995; Veikkola et al. 2000). Cultured human microvascular endothelial cells constitutively express all three VEGFRs (Hewett and Murray 1996), which may be a sign of cellular activation associated with culture conditions. These expression patterns are not altered after stimulation with VEGF-A of endothelial cells in vitro (Hewett and Murray 1996). In our in vivo model, all three members of the VEGFR family were upregulated in pre-existing iris vessels after VEGF-A treatment, including VEGFR-3, for which VEGF-A has no affinity.

Pericytes were previously regarded to be recruited only in the maturation phase of angiogenesis. Several studies, however, show that pericytes accompany endothelial cells in newly formed sprouting capillaries (Schlingemann et al. 1990b,1991,1996; Nehls and Drenckhahn 1991; Nehls et al. 1992; Witmer et al. 2001,2002a,b; Tsai et al. 2002), suggesting an important role for pericytes in early steps of blood vessel formation. In addition to endothelial cell activation, activation and hypertrophy of pericytes in sprouting vessels was demonstrated by increased staining of NG2 proteoglycan and PDGFR-β (Schlingemann et al. 1990b; Sundberg et al. 1993). Previous studies have shown in vitro and in vivo that pericytes express VEGFR-1 as well (Nomura et al. 1995; Takagi et al. 1996; Grosskreutz et al. 1999; Ogata et al. 2001; Witmer et al. 2002b). These findings support our suggestion that VEGFR-1 is expressed on pericytes in iris microvessels, along with endothelial cells. This may imply that VEGF-A acts directly on pericytes (Benjamin et al. 1998).

VEGFR-2 was expressed at low levels in the vasculature of the iris of control eyes, whereas VEGFR-2 is absent in the vasculature of monkey retina (Witmer et al. 2002a). This observation may explain differences in early responses of these two tissues to VEGF-A. In monkey retina, VEGF-A treatment leads to increased permeability, whereas neovascularization is not observed in this model after 9 days (Hofman et al. 2000,2001). However, VEGF-A injections in the eye lead to rapid development of iris neovascularization, which may be mediated by the constitutively expressed VEGFR-2. VEGF-A is considered to mediate iris neovascularization in human patients with retinal ischemia due to central retinal vein occlusion (Aiello et al. 1994) and in other pathological conditions that are not associated with retinal neovascularization, such as uveal melanoma (Vinores et al. 1995). As VEGFR-2 mediates the mitogenic signal of VEGF-A, our observations indicate that different levels of constitutive VEGFR-2 expression in iris and retina could explain these observations.

Figure 7

Summary of the findings of the present study. Schematic representation of the endothelial and pericyte phenotype in a pre-existent capillary and adjacent angiogenic sprout. Note the differential expression of key molecules in endothelial cells and pericytes in the quiescent state in comparison with the angiogenic state. (Schlingemann et al. 1990a, Witmer et al. 2003) (Reproduced with permission).

VEGFR-1 and −2 are the functional receptors of VEGF-A, whereas the ligands of VEGFR-3 are VEGF-C and -D. VEGF-C has a strong chemotactic effect on VEGFR-3-overexpressing endothelial cells in vitro (Kroon et al. 1999). In the adult, VEGFR-3 is mainly expressed in lymphatic endothelium and vascular endothelium in several types of tumors (Lymboussaki et al. 1998; Salven et al. 1998; Valtola et al. 1999; Veikkola and Alitalo 1999). In our study, after VEGF-A exposure, VEGFR-3 was expressed by pre-existing vascular endothelium of the iris and very strongly in the sprouting vasculature at the iris surface. This may indicate involvement of VEGFR-3 in migration of endothelial cells in VEGF-A-induced angiogenesis (Witmer et al. 2001).

Basement membrane degradation and subsequent migration of endothelial cells and pericytes through the extracellular matrix are the next steps in the angiogenic process. Endothelial cells and possibly pericytes need active proteases to hydrolyze the extracellular matrix proteins during migration. Proteases that are upregulated in endothelial cells in vitro by VEGF-A include members of the plasminogen system, such as uPA and its receptor uPAR (Mignatti and Rifkin 1996; Kroon et al. 1999). In addition, several matrix metal-loproteinases (Pepper 2001a,b) and cathepsin B activity have been associated with angiogenesis (Keppler et al. 1996; Hazen et al. 2000). In the present study, the pre-existing iris vasculature in VEGF-A-injected eyes showed a somewhat stronger expression of tPA, but tPA was absent in sprouting vessels at the iris surface. This may be an indication that tPA activity is not involved in migration of endothelial cells in the sprouting phase of angiogenesis, as was previously suggested by in vitro experiments (Koolwijk et al. 2001). In contrast, uPA expression was present in sprouting vessels in a pattern suggesting positivity in both pericytes and endothelial cells. Although protein expression of these proteases is not a direct marker of their activity (Hazen et al. 2000; Bleeker et al. 2000), our IHC observations may indicate that uPA of both pericytes and endothelial cells contributes to protease activation in the angiogenic process.

In addition to proteases, vascular cells express integrins known to be involved in cell migration and cell signaling during angiogenesis (Senger et al. 1996; Max et al. 1997; Byzova et al. 2000). In our study, vascular staining of the integrins α_vβ₃ and α_vβ₅ was stronger in VEGF-A-injected eyes than in control eyes. It is remarkable that both uPA and the integrins studied were upregulated at the protein level in both stationary and migrating cells in pre-existing and newly formed vessels in the iris after VEGF-A treatment. From in vitro studies it is known that endothelial cells upregulate the integrins α_vβ₃ and α_vβ₅ in response to growth factors (Eliceiri and Cheresh 2000), although upregulation of α_vβ₅ is less pronounced than α_vβ₃ (Friedlander et al. 1995; Eliceiri and Cheresh 2000; Walton et al. 2000). It has previously been suggested that different pathways of angiogenesis exist in vivo because angiogenesis in the mouse cornea and chorioallantoic membrane models induced by basic fibroblast growth factor or tumor necrosis factor-α depends on α_vβ₃, whereas angiogenesis initiated by VEGF-A depends on α_vβ₅ (Friedlander et al. 1995). Our observation that in iris angiogenesis after VEGF-A treatment staining of α_vβ₃ was much higher than that of α_vβ₅ is not in line with this association of VEGF-A and α_vβ₅.

After formation of vascular sprouts, the final phase of angiogenesis involves maturation and differentiation. Pericytes are considered to appear in angiogenesis only in this final stage, attracted via PDGFR-β signaling by endothelium-derived PDGF-BB (Hirschi and D'Amore 1996; Benjamin et al. 1998), to induce maturation of blood vessels, decrease of permeability (Thurston et al. 2000), and endothelial differentiation, by production of angiopoietin-1 and activation of TGF-β (Yancopoulos et al. 2000). This late role of pericytes was supported by observations that pericytes can inhibit endothelial proliferation in vitro via TGF-β (Antonelli-Orlidge et al. 1989). The absence of α-SMA staining at the front of growing vascular sprouts and in tumor vessels is generally interpreted as a sign of absence of pericytes and thus as a marker of angiogenesis and vessel immaturity (Benjamin et al. 1999). However, this study suggests that NG2 proteoglycanpositive pericytes are already present and activated in the front of newly formed iris vessels, and that these angiogenic pericytes do not express α-SMA (Schlingemann et al. 1991). Therefore, under angiogenic conditions, NG2 proteoglycan and PDGFR-β may be better markers for pericytes, whereas α-SMA is probably only expressed in a more stable and mature phenotype of pericytes, which develops when the newly formed vessels mature. Our results suggest that pericytes have an early role in angiogenesis and that they can differentiate into an angiogenic phenotype in a similar way as do endothelial cells. Expression of VEGFR-1 by pericytes may allow direct induction by VEGF-A or related factors such as placental growth factor (PlGF) of this phenotype and related angiogenic functions.

Angiopoietin receptor Tie-2 is thought to induce stabilization of primitive endothelial tubes, reduce permeability, and induce maturation on binding of angiopoietin-1 (Jain and Munn 2000; Thurston et al. 2000). Mouse embryos lacking Tie2 develop a rather normal vasculature but fail to undergo further remodeling (Sato et al. 1995). In this respect, the absence of Tie-2 in newly formed iris vessels is consistent with this stabilizing and remodeling function, as newly formed vessels are still immature. On the other hand, Tie2, through binding of angiopoietin-2, has also been proposed to be involved in destabilization of vessels allowing angiogenesis (Carmeliet 2000), a notion not supported by our observations.

In conclusion, our study shows that proteins, which play a role in angiogenesis, are upregulated in endothelial cells and pericytes in both pre-existing and newly formed iris vasculature after VEGF-A treatment. In several respects, our findings throw new light on the complex cellular process of angiogenesis as it occurs in vivo. VEGF-A induces hypertrophy and loss of barrier function in pre-existing vessels, and induces angiogenic sprouting, characterized by endothelial cells that lack expression of tPA and Tie-2, and pericytes that lack α-SMA expression, and by marked endothelial expression of VEGFR-3. Pericytes appear to play a significant role, next to endothelial cells, in immature sprouting blood vessels. These insights into the mechanism behind angiogenesis may raise new potential strategies into an attempt to inhibit (ocular) neovascularization.

Footnotes

Acknowledgements

Supported by the Haagsch Oogheelkundig Fonds, the Landelijke Stichting voor Blinden en Slechtzienden, the Rotterdamse Blindenpenning, the Donders Fonds Utrecht, the Edward and Marianne Blaauwfonds, and the Diabetes Fonds Nederland (grants 95.103 and 99.050).

We wish to thank Prof Dr K. Alitalo, Dr H.A. Weich, Prof Dr S. Ferrone, Prof Dr M.A. Horton, Dr K. Rubin, Prof Dr V.W.M. van Hinsbergh, Dr J.J. Emeis, and Dr L. Andersson for providing antibodies, and T. Put for preparing the microphotographs.

References

Adamis

Shima

Tolentino

Gragoudas

Ferrara

Folkman

D'Amore

. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66–71

Aiello

Avery

Arrigg

Keyt

Jampel

Shah

Pasquale

. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487

Albrecht

Seulberger

Schwarz

Risau

(1990) Correlation of blood-brain barrier function and HT7 protein distribution in chick brain circumventricular organs. Brain Res 535:49–61

Antonelli-Orlidge

Saunders

Smith

D'Amore

(1989) An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86:4544–4548

Ausprunk

Folkman

(1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53–65

Baker

Bergin

Leaper

(2000) Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 53:307–312

Balabanov

Dore-Duffy

(1998) Role of the CNS microvascular pericyte in the blood-brain barrier. J Neurosci Res 53:637–644

Benjamin

Golijanin

Itin

Pode

Keshet

(1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159–165

Benjamin

Hemo

Keshet

(1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591–1598

10.

Bleeker

Hazen

Kohler

Van Noorden

(2000) Direct comparison of the sensitivity of enzyme histochemical and immunohistochemical methods: cathepsin B expression in human colorectal mucosa. Acta Histochem 102:247–257

11.

Byzova

Goldman

Pampori

Thomas

Bett

Shattil

Plow

(2000) A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 6:851–860

12.

Carmeliet

(2000) Mechanisms of angiogenesis and arteriogenesis. Nature Med 6:389–395

13.

Diaz–Flores

Gutierrez

Varela

(1994) Angiogenesis: an update. Histol Histopathol 9:807–843

14.

Dvorak

Brown

Detmar

Dvorak

(1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039

15.

Eliceiri

Cheresh

(2000) Role of alpha v integrins during angiogenesis. Cancer J Sci Am 6(suppl 3):S245–249

16.

Ferrara

(1999) Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 237:1–30

17.

Friedlander

Brooks

Shaffer

Kincaid

Varner

Cheresh

(1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500–1502

18.

Grosskreutz

Anand–Apte

Duplaa

Quinn

Terman

Zetter

D'Amore

(1999) Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 58:128–136

19.

Harik

Hall

Richey

Andersson

Lundahl

Perry

(1993) Ontogeny of the erythroid/HepG2-type glucose transporter (GLUT-1) in the rat nervous system. Brain Res Dev Brain Res 72:41–49

20.

Hazen

Bleeker

Lauritzen

Bahns

Song

Jonker

Van Driel

. (2000) Comparative localization of cathepsin B protein and activity in colorectal cancer. J Histochem Cytochem 48:1421–1430

21.

Hewett

Murray

(1996) Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells. Biochem Biophys Res Commun 221:697–702

22.

Hirschi

D'Amore

(1996) Pericytes in the microvasculature. Cardiovasc Res 32:687–698

23.

Hofman

Blaauwgeers

Tolentino

Adamis

Nunes Cardozo

Vrensen

GFJM

Schlingemann

(2000) VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Curr Eye Res 21:637–645

24.

Hofman

Blaauwgeers

Vrensen

GFJM

Schlingemann

(2001) Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and in VEGF-A induced retinopathy in monkeys. Ophthalm Res 33:156–162

25.

Jain

Munn

(2000) Leaky vessels? Call Ang1! Nature Med 6:131–132

26.

Keppler

Sameni

Moin

Mikkelsen

Diglio

Sloane

(1996) Tumor progression and angiogenesis: cathepsin B & Co. Biochem Cell Biol 74:799–810

27.

Koolwijk

Kapiteijn

Molenaar

van Spronsen

van der Vecht

Helmerhorst

Van Hinsbergh

(2001) Enhanced angiogenic capacity and urokinase-type plasminogen activator expression by endothelial cells isolated from human endometrium. J Clin Endocrinol Metab 86:3359–3367

28.

Kroon

Koolwijk

Van Goor

Weidle

Collen

Van der Pluijm

van Hinsbergh

VWM

(1999) Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol 154:1731–1742

29.

Kumagai

Glasgow

Pardridge

(1994) GLUT1 glucose transporter expression in the diabetic and nondiabetic human eye. Invest Ophthalmol Vis Sci 35:2887–2894

30.

Lindahl

Johansson

Leveen

Betsholtz

(1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242–245

31.

Lymboussaki

Partanen

Olofsson

Thomas–Crusells

Fletcher

De Waal

Kaipainen

. (1998) Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol 153:395–403

32.

Max

Gerritsen

Nooijen

Goodman

Sutter

Keilholz

Ruiter

. (1997) Immunohistochemical analysis of integrin alphav beta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 71:320–324

33.

Mignatti

Rifkin

(1996) Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Prot 49:117–137

34.

Miller

Adamis

Shima

D'Amore

Moulton

O'Reilly

Folkman

. (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574–584

35.

Nakata

Ito

Fujimori

Shingu

Kajikawa

Adachi

Matsuyama

. (1998) Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer 79:179–186

36.

Nehls

Denzer

Drenckhahn

(1992) Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res 270:469–474

37.

Nehls

Drenckhahn

(1991) Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin. J Cell Biol 113:147–154

38.

Nomura

Yamagishi

Harada

Hayashi

Yamashima

Yamashita

Yamamoto

(1995) Possible participation of auto-crine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 270:28316–28324

39.

Ogata

Tombran–Tink

Nishikawa

Nishimura

Mitsuma

Sakamoto

Matsumura

(2001) Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 132:378–382

40.

Ortega

Hutchings

Plouet

(1999) Signal relays in the VEGF system. Front Biosci 4:D141–152

41.

Ortega

Jonca

Vincent

Favard

Ruchoux

Plouet

(1997) Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am J Pathol 151:1215–1224

42.

Paku

Paweletz

(1991) First steps of tumor-related angiogenesis. Lab Invest 65:334–346

43.

Paweletz

Knierim

(1989) Tumor-related angiogenesis. Crit Rev Oncol Hematol 9:197–242

44.

Pepper

(2001a) Extracellular proteolysis and angiogenesis. Thromb Haemost 86:346–355

45.

Pepper

(2001b) Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arter Thromb Vasc Biol 21:1104–1117

46.

Pepper

Ferrara

Orci

Montesano

(1991) Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902–906

47.

Plate

Warnke

(1997) Vascular endothelial growth factor. J Neurooncol 35:365–372

48.

Risau

(1997) Mechanisms of angiogenesis. Nature 386:671–674

49.

Salven

Lymboussaki

Heikkila

Jaaskela–Saari

Enholm

Aase

von Euler

. (1998) Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:103–108

50.

Sato

Tozawa

Deutsch

Wolburg–Buchholz

Fujiwara

Gendron–Maguire

Gridley

. (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70–74

51.

Schlingemann

Dingjan

Emeis

Blok

Warnaar

Ruiter

(1985) Monoclonal antibody PAL-E specific for endothelium. Lab Invest 52:71–76

52.

Schlingemann

Hofman

Anderson

Troost

Van der Gaag

(1997) Vascular expression of endothelial antigen PAL-E indicates absence of blood-ocular barriers in the normal eye. Ophthalm Res 29:130–138

53.

Schlingemann

Oosterwijk

Wesseling

Rietveld

Ruiter

(1996) Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol 179:436–442

54.

Schlingemann

Rietveld

De Waal

Bradley

Skene

Davies

Greaves

. (1990a) Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 62:690–696

55.

Schlingemann

Rietveld

De Waal

Ferrone

Ruiter

(1990b) Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136:1393–1405

56.

Schlingemann

Rietveld

Kwaspen

van de Kerkhof

de Waal

Ruiter

(1991) Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 138:1335–1347

57.

Senger

Ledbetter

Claffey

Papadopoulos–Sergiou

Peruzzi

Detmar

(1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149:293–305

58.

Sone

Deo

Kumagai

(2000) Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. Invest Ophthalmol Vis Sci 41:1876–1884

59.

Spyridopoulos

Brogi

Kearney

Sullivan

Cetrulo

Isner

Losordo

(1997) Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol 29:1321–1330

60.

Sundberg

Ljungstrom

Lindmark

Gerdin

Rubin

(1993) Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 143:1377–1388

61.

Suzuma

Takagi

Otani

Honda

(1998) Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci 39:1028–1035

62.

Takagi

King

Aiello

(1996) Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 45:1016–1023

63.

Takano

Tsuboi

Tomono

Mitsui

Nose

(2000) Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 82:1967–1973

64.

Thurston

Rudge

Ioffe

Zhou

Ross

Croll

Glazer

. (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nature Med 6:460–463

65.

Tolentino

Miller

Gragoudas

Chatzistefanou

Ferrara

Adamis

(1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114:964–970

66.

Tsai

JYY

Yamamoto

Fariss

Hickman

Pagan–Mercado

(2002) Using SMAA-GFP mice to study pericyte coverage of retinal vessels. Invest Ophthalmol Vis Sci 43:S1929

67.

Valtola

Salven

Heikkilä

Taipale

Joensuu

Rehn

Pihlajaniemi

. (1999) VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154:1381–1390

68.

Van Hinsbergh

Koolwijk

Hanemaaijer

(1997) Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS 79:391–411

69.

Veikkola

Alitalo

(1999) VEGFs, receptors and angiogenesis. Semin Cancer Biol 9:211–220

70.

Veikkola

Karkkainen

Claesson–Welsh

Alitalo

(2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60:203–212

71.

Vinores

Kuchle

Mahlow

Chiu

Green

Campochiaro

(1995) Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol 147:1289–1297

72.

Walton

Corjay

Mohamed

Mousa

Santomenna

Reilly

(2000) Hypoxia induces differential expression of the integrin receptors alpha(vbeta3) and alpha(vbeta5) in cultured human endothelial cells. J Cell Biochem 78:674–680

73.

Witmer

Blaauwgeers

Weich

Alitalo

Vrensen

GFJM

Schlingemann

(2002a) Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 43:849–857

74.

Witmer

Dai

Weich

Vrensen

Schlingemann

(2002b) Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 50:767–778

75.

Witmer

Van Blijswijk

Hofman

Dai

Partanen

Vrensen

GFJM

Schlingemann

(2001) VEGFR-3 in adult angiogenesis. J Pathol 195:490–497

76.

Witmer

Vrensen

GFJM

Van Noorden

CJF

Schlingemann

(2003) Vascular endothelial growth factors and angiogenesis in eye disease. Prog Ret Eye Res 22:1–29

77.

Yancopoulos

Davis

Gale

Rudge

Wiegand

Holash

(2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248

In Vivo Angiogenic Phenotype of Endothelial Cells and Pericytes Induced by Vascular Endothelial Growth Factor-A

Abstract

Keywords

Materials and Methods

Monkey Tissue Samples

Immunohistochemistry

Results

Biomicroscopy

Immunohistochemistry

Markers of Vascular Permeability

Markers of Cellular Activation

Proteins Involved in Fibrinolysis and Breakdown of Extracellular Matrix

Proteins Involved in Endothelial and Pericyte Migration

Markers of Maturation and Differentiation

Discussion

Footnotes

Acknowledgements

References